Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
REGULATORY
Japan Panel Recognizes One More Death Possibly Linked to COVID Jab
A Japanese health ministry panel on October 17 determined the death of a 72-year-old man as being possibly linked to a COVID-19 vaccination, bringing the total number of mortality cases to four. The government will offer one-time death compensation and…
To read the full story
Related Article
- MHLW Panel OKs 192 More Health Damage Claims for COVID-19 Vaccines
April 24, 2023
- Relief Claims OK’ed for 12 More Deaths Possibly Linked to COVID Jabs
April 18, 2023
- MHLW Panel OKs 184 More Health Damage Claims for COVID-19 Jabs
March 22, 2023
- Japan Damage Relief Panel Recognizes 11 More Deaths Possibly Tied to COVID Jabs
March 16, 2023
- Japan Panel Recognizes 10 More Deaths Possibly Linked to COVID Jabs
February 13, 2023
- MHLW Panel OKs 79 More Health Damage Claims for COVID-19 Vaccines
February 8, 2023
- MHLW Panel OKs 62 More Health Damage Claims for COVID-19 Vaccines
January 24, 2023
- MHLW Panel OKs 64 More Health Damage Claims for COVID-19 Vaccines
January 16, 2023
- Japan Panel Recognizes 5 More Deaths Possibly Tied to COVID Vaccines
January 13, 2023
- Japan to Boost Review of Health Damage Claims for COVID-19 Vaccines
January 12, 2023
- MHLW Panel OKs 70 More Health Damage Claims for COVID-19 Vaccines
December 26, 2022
- Japan Panel Recognizes 5 More Deaths Possibly Linked to COVID Jabs, 1st for 20s
December 13, 2022
- MHLW Panel OKs 111 More Health Damage Claims for COVID-19 Vaccines
November 28, 2022
- Japan Panel Recognizes 6 More Deaths Possibly Linked to COVID Vaccines
November 8, 2022
- MHLW Panel OKs 100 More Health Damage Claims for COVID-19 Vaccines
October 31, 2022
- MHLW Panel OKs 65 More Health Damage Claims for COVID-19 Vaccines
September 26, 2022
- MHLW Panel Recognizes 2 More Deaths Linked to COVID Jabs
September 13, 2022
- MHLW Panel OKs 60 More Health Damage Claims for COVID-19 Vaccines
July 29, 2022
- Japan Panel Recognizes 1st Death Linked to COVID Vaccination
July 26, 2022
- MHLW Panel OKs 56 More Health Damage Claims for COVID-19 Vaccines
June 27, 2022
- MHLW Panel OKs 62 More Health Damage Claims for COVID-19 Vaccines
June 3, 2022
- MHLW Panel OKs 84 More Health Damage Claims for COVID-19 Vaccines
March 28, 2022
- MHLW OKs 48 More Health Damage Claims for COVID-19 Vaccines
February 28, 2022
- MHLW OKs 115 More COVID-19 Vaccine Health Damage Claims
February 1, 2022
- MHLW Panel OKs 81 More COVID-19 Vaccine Health Damage Claims
October 25, 2021
- Panel OKs 37 More COVID-19 Jab Health Damage Claims for Compensation
September 14, 2021
- Japan Panel OKs COVID-19 Vaccine Health Damage Claims for First Time
August 20, 2021
REGULATORY
- Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
- Japan’s Healthcare Spending Hits Record 48.8 Trillion Yen in FY2024
November 2, 2026
- PMDA Renews Warning on Off-Label GLP-1 Use amid Adverse Event Reports
November 2, 2026
- PMDA Halts Medical Device Application Platform after Unauthorized Access
October 30, 2026
- Drug Makers Can Refuse Diabetes Drug Supply over Improper Prescribing: JFTC
October 30, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…